| ARTICLE |
|
| Year : 2013 | Volume
: 15
| Issue : 63 | Page : 83--90 |
Intratympanic treatment for tinnitus: A review
Thomas Meyer
Auris Medical AG, Basel, Switzerland
Correspondence Address:
Thomas Meyer
Auris Medical AG, Falknerstrasse 4, 4001 Basel
Switzerland
 Source of Support: Auris Medical AG, Conflict of Interest: The author is the Managing Director and a major shareholder of Auris Medical
AG which sponsored one clinical trial mentioned in the present article (Mühlmeier et al, 2011)  | Check |
DOI: 10.4103/1463-1741.110285
Since the 1940s, various attempts have been made to treat peripheral tinnitus by way of intratympanic injection. This administration procedure requires only low concentrations of medication, thanks to the highly targeted delivery to the site of action and comes with minimal systemic exposure. While different compounds have been tested for their effects on tinnitus by intratympanic injection, there has been no breakthrough so far. Accordingly, the clinical use of intratympanic tinnitus treatments has remained limited to date. A more widespread adoption of this approach will require the development of specific medications for peripheral tinnitus, as well as proof of safety and efficacy, which would be determined from randomized controlled clinical trials.
[FULL TEXT] [PDF]*
|
Search Pubmed for
